Koch's 'disruptive' VC bets $110M on one of Flagship's new, big computational startups
David Berry joined Flagship as a Harvard and MIT wunderkind in 2005 and by now he’s been at the firm almost as long as anyone not named Noubar. He’s played a hand in some of their biggest startups, including Seres, Omega, KSQ, Evelo and, of course, Moderna.
Flagship is known for its flash, but over the last couple years, Berry has been quietly building a computational startup in Boston that he thinks can remake drug development in a way that, for all the buzz, machine learning and artificial intelligence have yet to do.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.